Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Aoife Brennan BCh MMSc
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 28
- Beta
- 0.07
- Country
- US
- Piotroski score
- 2 / 9 (Weak)
- Altman Z-score
- 50.84
Financials
Net Income
$-13.50MEBITDA
$-15.33MFree Cash Flow
$-10.81MEPS (diluted)
$-0.18Shares Outstanding (diluted)
76.15M+553.0%Operating Expenses
$15.36MCash & Debt
$183.12MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $-59.85M | $-0.88 |
| 2024 | $0.00 | $-73.90M | $-1.53 |
| 2023 | $0.00 | $-35.12M | $-1.30 |
| 2022 | $0.00 | $-45.24M | $-1.72 |
| 2021 | $0.00 | $-47.48M | $-4.24 |
| 2020 | $0.00 | $-20.67M | $-1.97 |
| 2019 | $0.00 | $-6.55M | $-0.56 |
Valuation
CLYMhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
70+40.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·10d ago·Positive
Climb Bio: Others Proved APRIL Works, So The Bet Is On The 12-Week Dosing Interval Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and budoprutug for broader autoimmune indications. CLYM is well-capitalized with $239.2M in cash, providing operational runway into 2H 2028 and enabling progression through key clinical milestones without near-term dilution. CLYM116's modeled quarterly dosing and Budoprutug's CD19 differentiation present compelling produc…
View source ↗ - Newsglobenewswire.com·15d ago·Positive
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation
View source ↗ - Newsmarketbeat.com·44d ago·Negative
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug Climb Bio NASDAQ: CLYM presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China.
View source ↗ - Newsbenzinga.com·44d ago·Positive
Climb Bio's Kidney Disease Therapy Gets Support for Extended Dosing Schedule Climb Bio Inc. (NASDAQ:CLYM) on Thursday released preliminary data from its ongoing Phase 1 trial assessing CLYM116, while revealing updated strategic plans for treating IgA nephropathy, a kidney disease.
View source ↗ - Newsglobenewswire.com·44d ago·Positive
Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy ~29-day half-life Single 320 mg dose of CLYM116 drove near-complete APRIL suppression and 60-75% IgA/Gd-IgA1 suppression through 12 weeks CLYM116 generally well-tolerated, with no serious adverse events, dose-limiting toxicities, or hypogammaglobulinemia Phase 2 NAVIGATE-2 trial in IgA nephropathy ongoing; anticipate initial data in H1 …
View source ↗ - Newsglobenewswire.com·45d ago·Neutral
Climb Bio to Present at Upcoming Investor Conferences WELLESLEY HILLS, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that members of its executive team will participate in the upcoming conferences detailed below.
View source ↗
Earnings
Wed, Nov 11(in 3 weeks)
Consensus estimate $-0.19 per share
Typical surprise +13.3% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.18 vs $-0.21beat
- Thu, May 7$-0.20 vs $-0.26beat
- Thu, Mar 5$-0.26 vs $-0.20miss
- Thu, Nov 6$-0.19 vs $-0.16miss
- Tue, Aug 12$-0.13 vs $-0.19beat
- Wed, May 14$-0.31 vs $-0.15miss
Estimates and results for CLYM via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CLYM officers and directors.
- Bought
- $780k
- Sold
- $2.7m
3 trades
10 trades
- Thomas Stephen Basilsold
- Brennan Aoifesold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Thomas Stephen Basilsold
- Ra Capital Management, L.p.bought
- Ra Capital Management, L.p.bought
65 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in CLYM.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.